A Pilot Study Evaluating Safety of Sitagliptin Combined With Peg-IFN Alfa-2a + Ribavirin in Chronic Hepatitis C Patients

NCT01567540 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

3

Enrollment

OTHER_GOV

Sponsor class

Stopped New treatments available, which prevents additional recruitment.

Conditions

Hepatitis C

Interventions

DRUG: Sitagliptin

Sponsor

Institut National de la Santé Et de la Recherche Médicale, France